Sponsors (2)
The bill strengthens FDA oversight and patient safety for compounded drugs through caps, reporting, inspections, and fee authority, at the cost of higher compliance and administrative burdens, potential price increases, and reduced access for some patients who rely on compounded alternatives.
Patients who receive compounded drugs (including those with chronic conditions) face lower risk of contaminated or unsafe products because the bill caps non‑patient‑specific compounding, requires data reporting, mandates inspections of large outsourcing facilities, and enables higher fees to fund inspections and quality controls.
Hospitals, health systems, and prescribers gain more consistent regulatory oversight and supply reliability from required inspections, reporting, and improved FDA visibility into high‑volume compounders.
Manufacturers of approved, commercially available drugs face reduced unfair competitive substitution because the bill narrows when compounded products are treated as copies of commercial drugs.
Patients with unique or chronic needs (and the hospitals that serve them) could face reduced access to needed compounded alternatives if practitioners hit the new 20‑unit monthly cap on non‑patient‑specific compounding.
Pharmacies, outsourcing facilities, and compounding practitioners will face higher costs from inspections, registration, fees, and compliance, which may be passed on to patients or reduce local service availability.
Pharmacies, facilities, and prescribers must collect and submit compounding data and coordinate across state rules, creating recurring administrative burdens and regulatory friction for interstate compounding and dispensing.
Based on analysis of 5 sections of legislative text.
Introduced February 5, 2026 by James E. Banks · Last progress February 5, 2026
Imposes new limits, reporting, inspection, registration, and fee-setting authority to tighten federal oversight of drug compounding. It caps how often pharmacies can compound products that are “essentially a copy” of commercially available drugs, requires annual reports for certain out-of-state compounding, creates inspection and registration rules for high-volume outsourcing facilities, and lets the HHS Secretary set a base fee to fund safety activities for compounded products. The law defines when a compounded product counts as an “essentially a copy,” exempts on-premises hospital compounding from one reporting rule, requires initial and biennial inspections for large-scale outsourcing facilities, removes a registration/reporting exemption for outsourcing facilities, and delegates discretion to the Secretary to set a base establishment fee to support safety work.